Try our Advanced Search for more refined results
Bristol-Myers Squibb Company et al v. Mylan Pharmaceuticals Inc.
Case Number:
1:17-cv-00379
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
October 18, 2018
Bristol-Myers, Pfizer's Blood Thinner IP Suit Axed Over Venue
A Delaware federal judge tossed a lawsuit filed by Bristol-Myers Squibb Co. and Pfizer Inc. seeking to block Mylan Pharmaceuticals Inc. from making a generic version of their patented blood thinner Eliquis, finding on Thursday that the suit was filed in the wrong venue in light of the U.S. Supreme Court's TC Heartland ruling.
-
September 18, 2017
3 Takeaways From Delaware's TC Heartland Venue Guidance
The District of Delaware's chief judge recently held in two rulings that companies must have permanent ties to the state to face patent suits there following the U.S. Supreme Court's TC Heartland ruling, and his analysis could keep many generic-drug cases in his court. Here's what attorneys can learn from the decisions.
-
September 12, 2017
Del. Chief Judge Sets Post-TC Heartland Venue Guidelines
The District of Delaware’s chief judge said Monday that after a recent U.S. Supreme Court ruling, companies must have a permanent and physical presence in the state to be sued there for patent infringement, so he transferred one case and ordered further discovery in another.